The Role of Chemotherapy for Metastatic Disease
作者： Catalin Mihalcioiu
DOI: 10.1007/978-1-4614-3685-0_23
关键词:
摘要: Advances in understanding the molecular and biochemical changes underlying metastatic disease resulted development of promising chemotherapeutic agents. Treatment has improved significantly with addition drugs that affect specific processes like nucleotide bases, DNA (synthesis, degradation repair) as well microtubules
springer.com
sci-hub.st 参考文章(139)
Cognetti F, Serrone L, Zeuli M, Sega Fm, Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Journal of Experimental & Clinical Cancer Research. ,vol. 19, pp. 21- 34 ,(2000)
Katherine L. Seley, Sylvester L. Mosley, Purine Analogues and Their Role in Methylation and Cancer Chemotherapy Springer, Boston, MA. pp. 178- 186 ,(2005) , 10.1007/0-387-27443-X_13
Thierry Dorval, Sylvie N�grier, Christine Chevreau, Marie-Fran�oise Avril, Daniel Baume, Didier Cupissol, Ralph Oskam, Ria de Peuter, Jan Vinke, Alain Herrera, Bernard Escudier, Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study Cancer. ,vol. 85, pp. 1060- 1066 ,(1999) , 10.1002/(SICI)1097-0142(19990301)85:5<1060::AID-CNCR8>3.0.CO;2-2
Kyle D. Holen, Michael R. Harrison, Glenn Liu, Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clinical advances in hematology & oncology. ,vol. 7, pp. 54- 64 ,(2009)
E. Engelsman, J.C.M. Klijn, R.D. Rubens, J. Wildiers, L.V.A.M. Beex, M.A. Nooij, N. Rotmensz, R. Sylvester, “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 966- 970 ,(1991) , 10.1016/0277-5379(91)90259-G
Tom Crosby, Reg Fish, Bernadette Coles, Malcolm Mason, Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews. ,vol. 2018, ,(2000) , 10.1002/14651858.CD001215
N M Bleehen, E S Newlands, S M Lee, N Thatcher, P Selby, A H Calvert, G J Rustin, M Brampton, M F Stevens, Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. Journal of Clinical Oncology. ,vol. 13, pp. 910- 913 ,(1995) , 10.1200/JCO.1995.13.4.910
Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Claudia A. Seipp, Jan H. Einhorn, Donald E. White, Seth M. Steinberg, Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b Journal of Clinical Oncology. ,vol. 17, pp. 968- 975 ,(1999) , 10.1200/JCO.1999.17.3.968
J.-M. Nabholtz, H. J. Senn, W. R. Bezwoda, D. Melnychuk, L. Deschênes, J. Douma, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy Journal of Clinical Oncology. ,vol. 17, pp. 1413- 1424 ,(1999) , 10.1200/JCO.1999.17.5.1413
J Aisner, V Weinberg, M Perloff, R Weiss, M Perry, A Korzun, S Ginsberg, J F Holland, Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. Journal of Clinical Oncology. ,vol. 5, pp. 1523- 1533 ,(1987) , 10.1200/JCO.1987.5.10.1523